A phase II study of sEphB4-HSA in metastatic castration-resistant prostate cancer (mCRPC)

被引：0
|
作者：
Burns, Michael C.
Sagar, Vinay
Jovanovic, Borko
Morgans, Alicia K.
VanderWeele, David James
Quinn, David I.
Stadler, Walter Michael
Abdulkadir, Sarki
Hussain, Maha H. A.
机构：
[1] Northwestern Univ, Chicago, IL 60611 USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA
[3] Northwestern Univ, Dept Prevent Med, Chicago, IL 60611 USA
[4] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[5] USC Norris Comprehens Canc Ctr, Los Angeles, CA USA
[6] Univ Chicago, Chicago, IL 60637 USA
[7] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 06期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS274
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Results of a phase II study of sunitinib (SU) maintenance after response to docetaxel in metastatic castration-resistant prostate cancer (mCRPC)
    Eigl, Bernhard J.
    Eliasziw, Misha
    North, Scott A.
    Trudeau, Marc G.
    Winquist, Eric
    Chi, Kim N.
    Ruether, Joseph D.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [32] SHR3680, a novel antiandrogen, for the treatment of metastatic castration-resistant prostate cancer (mCRPC): A phase I/II study
    Qin, Xiaojian
    Han, Weiqing
    Luo, Hong
    Du, Chuanjun
    Zou, Qing
    Sun, Zhongquan
    He, Chaohong
    Zhu, Shaoxing
    Chong, Tie
    Yao, Xin
    Wan, Ben
    Gu, Weijie
    Ye, Dingwei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [33] Preliminary phase II results of the CYPIDES study of ODM208 in metastatic castration-resistant prostate (mCRPC) cancer patients
    Fizazi, K.
    Bernard-Tessier, A.
    Barthelemy, P.
    Utriainen, T.
    Roubaud, G.
    Flechon, A.
    van der Voet, J. C. M.
    Mescam, G. Gravis
    Ratta, R.
    Jones, R. H.
    Parikh, O. A.
    Tanner, M. M. E.
    Garratt, C.
    Nevalaita, L.
    Pohjanjousi, P.
    Ikonen, T.
    Antonarakis, E. S.
    Cook, N.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1165 - S1165
  • [34] Multicenter phase II study of trabectedin in patients with metastatic castration-resistant prostate cancer
    Michaelson, M. D.
    Bellmunt, J.
    Hudes, G. R.
    Goel, S.
    Lee, R. J.
    Kantoff, P. W.
    Stein, C. A.
    Lardelli, P.
    Pardos, I.
    Kahatt, C.
    Nieto, A.
    Cullell-Young, M.
    Lewis, N. L.
    Smith, M. R.
    ANNALS OF ONCOLOGY, 2012, 23 (05) : 1234 - 1240
  • [35] Randomized phase II study of nintedanib in metastatic castration-resistant prostate cancer postdocetaxel
    Droz, Jean-Pierre
    Medioni, Jaques
    Chevreau, Christine
    De Mont-Serrat, Helene
    Merger, Michael
    Stopfer, Peter
    Kaiser, Rolf
    Oudard, Stephane
    ANTI-CANCER DRUGS, 2014, 25 (09) : 1081 - 1088
  • [36] A phase 2 study of onvansertib in combination with abiraterone and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).
    Einstein, David Johnson
    Choudhury, Atish Dipankar
    Saylor, Philip James
    Patterson, Jesse Christopher
    Croucher, Peter
    Ridinger, Maya
    Erlander, Mark G.
    Yaffe, Michael B.
    Bubley, Glenn
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [37] Phase I/II trial of enzalutamide (Enz) plus mifepristone (Mif) for metastatic castration-resistant prostate cancer (mCRPC)
    Serritella, Anthony
    Shevrin, Daniel H.
    Heath, Elisabeth I.
    Wade, James Lloyd
    Martinez, Elia
    Karrison, Theodore
    Stadler, Walter Michael
    Szmulewitz, Russell Zelig
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [38] A randomized phase 2 study of two doses of itraconazole in men with metastatic castration-resistant prostate cancer (mCRPC)
    Antonarakis, Emmanuel S.
    Heath, Elisabeth I.
    Smith, David C.
    Rathkopf, Dana
    Blackford, Amanda L.
    Danila, Daniel C.
    King, Serina
    Frost, Anja
    Ajiboye, A. Seun
    Zhao, Ming
    Mendonca, Janet
    Kachhap, Sushant K.
    Rudek, Michelle A.
    Carducci, Michael A.
    CANCER RESEARCH, 2012, 72
  • [39] Phase II trial of carfilzomib for metastatic castration-resistant prostate cancer (mCRPC) following androgen pathway inhibitors.
    Naik, Gurudatta
    Bae, Sejong
    De Shazo, Mollie R.
    Dixon, Pam
    Merritt, Lynn
    Sartor, A. Oliver
    Schnell, Frederick M.
    Sonpavde, Guru
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [40] ARN-509 in men with metastatic castration-resistant prostate cancer (mCRPC)
    Rathkopf, Dana E.
    Antonarakis, Emmanuel S.
    Shore, Neal D.
    Tutrone, Ronald
    Alumkal, Joshi J.
    Ryan, Charles J.
    Saleh, Mansoor N.
    Hauke, Ralph J.
    Maneval, Edna Chow
    Scher, Howard I.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
12345